Seagen and Astellas announce results from EV-302 study
Trial involves the use of Padcev and Keytruda among patients with certain types of urothelial cancer
Read More
Tag: EV-302
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
